<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002372</url>
  </required_header>
  <id_info>
    <org_study_id>264A</org_study_id>
    <nct_id>NCT00002372</nct_id>
  </id_info>
  <brief_title>A Study of 141W94 in Combination With Other Anti-HIV Drugs</brief_title>
  <official_title>A Phase I/II Screening Trial to Identify Potential Partner Compounds to Use in Combination With 141W94</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir,
      indinavir and nelfinavir after multiple oral dosing. To determine the steady-state
      pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141W94 after
      multiple oral dosing. To assess the safety and tolerability of multiple doses of 141W94 when
      combined with saquinavir, indinavir and nelfinavir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to receive open label 141W94 in combination with saquinavir,
      indinavir and nelfinavir. The randomized phase will be preceded by a single dose
      pharmacokinetic interaction study of 141W94 and indinavir in 12 patients. Data from this
      single dose investigation will be used to determine the dose of indinavir to be used in the
      randomized phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>48</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amprenavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed provided used with caution:

        Medications that may interact at CYP3A4 (either a substrate, inhibitor or inducer of the
        enzyme) should be used with caution.

        Patients must have:

          -  Documented HIV infection.

          -  CD4+ cell count &gt;= 200 cells/mm3.

             1. Anticipated need for treatment with cytotoxic chemotherapeutic agents within the
             study time period.

          -  Treatment with immunomodulating agents.

          -  Medications that should not be administered with 141W94:

        Terfenadine. Astemizole. Cisapride. Triazolam. Midazolam.
        Ergotamine/Dihydroergotamine-containing regimens. Antiretroviral drugs. Vitamin E
        supplements. Other experimental agents.

        Anticipated need for radiation therapy within the study time period.

        1. Prior protease inhibitors.

          -  Antiretroviral therapy within 2 weeks prior to entry.

          -  Treatment with cytotoxic chemotherapeutic agents within 4 weeks prior to entry.

        Radiation therapy within 4 weeks prior to entry. Current alcohol or illicit drug use that,
        in the opinion of the investigator, may interfere with the patient's ability to comply with
        the dosing and protocol evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Eron JJ, Haubrich R, Lang W, Pagano G, Millard J, Wolfram J, Snowden W, Pedneault L, Tisdale M. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):458-61.</citation>
    <PMID>11391165</PMID>
  </reference>
  <verification_date>November 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Indinavir</keyword>
  <keyword>Saquinavir</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>VX 478</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Amprenavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

